Join the Victoza group to help and get support from people like you.
Victoza News (Page 3)
Expanding Access to Obesity Medications Could Avert 42,000 Deaths/Year
THURSDAY, Nov. 7, 2024 – Expanding access to obesity medications such as glucagon-like peptide 1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide and GLP-1 receptor agonists could...
Guidance Issued for Safe Use of GLP-1 RAs in the Perioperative Period
TUESDAY, Nov. 5, 2024 – In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, recommendations are presented for the safe use of...
ACG: GLP-1 RAs Tied to Lower Risk for Early-Onset Colorectal Cancer
FRIDAY, Nov. 1, 2024 – Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of...
FDA Medwatch Alert: FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
October 2, 2024 -- The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection ...
GLP-1 RA Use Linked to Retained Gastric Contents During Endoscopies
FRIDAY, Oct. 4, 2024 – Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with the risk for retained gastric contents and inadequate bowel preparation during endoscopic...
Weight Reduction Varies for Patients Receiving Semaglutide, Liraglutide
FRIDAY, Sept. 13, 2024 – For patients with obesity receiving semaglutide or liraglutide, weight reduction at one year is associated with medication active agent, dosage, treatment indication, and...
Liraglutide Efficacious, Safe for Children Aged 6 to
THURSDAY, Sept. 12, 2024 – Liraglutide plus lifestyle intervention is efficacious for children aged 6 to
GLP-1 RA Use Linked to Lower Rates of Hyperkalemia in Type 2 Diabetes
MONDAY, Aug. 12, 2024 – Treatment with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with lower rates of hyperkalemia and a lower rate of renin-angiotensin system inhibitor...
FDA Medwatch Alert: Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions
ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see the list in...
FDA Approves Victoza (liraglutide) for the Treatment of Pediatric Patients 10 Years or Older with Type 2 Diabetes
June 17, 2019 – The U.S. Food and Drug Administration today approved Victoza (liraglutide) injection for treatment of pediatric patients 10 years or older with type 2 diabetes. Victoza is the first...
Victoza (liraglutide) is Approved to Reduce the Risk of Three Major Adverse Cardiovascular Events in Type 2 Diabetes Patients
PLAINSBORO, N.J., Aug. 25, 2017 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved a new indication for Victoza (liraglutide) to reduce the risk of major adverse cardiovascular...
Novo Nordisk Receives FDA Approval for Xultophy 100/3.6 (insulin degludec and liraglutide injection) for Type 2 Diabetes
PLAINSBORO, N.J., Nov. 21, 2016 /PRNewswire/ – Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application for...
FDA Medwatch Alert: Incretin Mimetic Drugs for Type 2 Diabetes: Early Communication - Reports of Possible Increased Risk of Pancreatitis and Pre-cancerous Findings of the Pancreas
ISSUE: FDA is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis and pre-cancerous cellular changes called pancreatic duct...
Victoza Label Updated to Include Data Showing Superior Efficacy When Compared to Januvia
Princeton, N.J. (April 9, 2012) /PRNewswire/ - Novo Nordisk received approval from the U.S. Food and Drug Administration (FDA) to update the product label for Victoza (liraglutide [rDNA origin]...
FDA Medwatch Alert: Victoza (liraglutide [rDNA origin]) Injection: REMS - Risk of Thyroid C-cell Tumors, Acute Pancreatitis
ISSUE: Novo Nordisk reminded healthcare professionals of important safety information about Victoza (liraglutide [rDNA origin]) injection required in a Risk Evaluation and Mitigation Strategy (REMS)....
Further information
Related condition support groups
Diabetes, Type 2, Cardiovascular Risk Reduction